Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Antibody Deficiency: later-stage trial registry

1 of 1 indexed Antibody Deficiency trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Antibody Deficiency: 1 US clinical trial tracked, 1 recruiting.

Antibody Deficiency is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Alabama at Birmingham, running 1 of these trials.

Enrollment posture brief

Registry condition antibody-deficiency

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Antibody Deficiency (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Antibody Deficiency

Antibody Deficiency lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Antibody Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Antibody Deficiency is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Antibody Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

20-valent pneumococcal conjugate vaccine Biological
1 trials

US sites by state

Facility locations filed on Antibody Deficiency trials. A trial with sites in several states counts in each.

Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Antibody Deficiency page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Antibody Deficiency condition card totals 1 registered trials; most-linked intervention 20-valent pneumococcal conjugate vaccine; top US site state Alabama. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.